Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026

How will the additional $137 million in potential U.S. government funding affect APLT's cash runway and burn rate? What dilution or share issuance might be required if the funding proposals are approved? How likely are the new funding proposals to be awarded, based on historical success rates for similar biotech grants? What impact could the funding announcements have on APLT’s share price in the short‑term and long‑term? How does APLT's current cash position and financing needs compare to peers in the biotech sector? What milestones does APLT need to achieve to secure the proposed funding, and what is the timeline? Will the additional funding accelerate any upcoming clinical trials or product milestones? How does the potential $137 million in funding compare to the company’s projected R&D spend for FY 2026? What are the potential risks if the funding proposals are rejected or delayed? How might this funding news affect analyst consensus and price targets for APLT? Are there any covenants or reporting requirements attached to the government funding that could impact operations? What is the market’s perception of APLT’s ability to convert these proposals into actual cash inflows?